Five analysts place USD 4.25 target on Geron stock

Published on 10/17/2026 at 22:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron's next date is November 4, 2026. Geron stock costs USD 1.17 on October 16, 2026, down 4.88 percent on Nasdaq.

Analyst view and scheduled date

Five analysts placed an average USD 4.25 target on Geron stock on October 15, 2026.
Geron's next reporting date is November 4, 2026.
Geron stock stood at USD 1.17 on October 16, 2026, down 4.88 percent on Nasdaq.
Geron's market capitalization was USD 751.7 million on October 16, 2026.

GERN, US3741631036, Illustration mit AI erstellt.

Five analysts placed an average target of USD 4.25 on Geron stock on October 15, 2026, according to StockAnalysis. The target stood 263.25 percent above the latest Nasdaq price of USD 1.17. Geron stock last traded at USD 1.17 on October 16, 2026 at 4:00 p.m. EDT, down 4.88 percent from the prior Nasdaq close.

Revenue expectations reach USD 60.70 million

For the third quarter of 2026, consensus revenue is USD 60.70 million and consensus earnings per share are minus USD 0.01, according to MarketBeat. The estimates give investors a measurable test for the next report, particularly because the company is still valued below its analyst target despite commercial revenue from RYTELO.

Stock sits 41.79 percent below its high

Geron's Nasdaq price ranged from USD 1.04 to USD 2.01 over the 52-week period ending October 16, 2026. At USD 1.17, the stock was 41.79 percent below its 52-week high and 12.50 percent above its 52-week low. Trading volume was 3,948,156 shares, compared with an average volume of 9,835,770 shares.

Valuation and November reporting date

Geron had a market capitalization of USD 751.7 million and a trailing price-to-earnings ratio of minus 11.74 on October 16, 2026. The company does not pay a dividend yield according to the quoted market figures. MarketBeat estimates Geron will report third-quarter 2026 results on November 4, 2026, before the Nasdaq opening bell.

Comparison with peers

GERN (Nasdaq, USD): minus 4.88 percent, P/E minus 11.74, market capitalization USD 751.7 million

Immunocore Holdings (Nasdaq, USD): minus 0.27 percent, P/E minus 154.49, market capitalization USD 1.5 billion

Kura Oncology (Nasdaq, USD): minus 6.39 percent, P/E minus 2.69, market capitalization USD 807.8 million

Price remains the key market marker

The target gap and the November reporting date provide the main reference points for the stock. The latest Nasdaq price was USD 1.17 on October 16, 2026 at 4:00 p.m. EDT, while the market capitalization was USD 751.7 million.